BACKGROUND: Sorafenib is the only FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). In clinical practice, dose reductions are often required, although there are limited efficacy data related to dose modifications. Given the prevalence of HCC in South Texas, we assessed the efficacy and safety of sorafenib therapy in relation to dose and Child Pugh (CP) score. METHODS: A retrospective analysis was done of advanced HCC patients, starting sorafenib at 400 mg twice daily, or at physician discretion at 400 mg daily, with the goal of titrating to twice daily. Overall survival (OS) and progression-free survival (PFS) were assessed. RESULTS: Among 107 patients, median OS (mOS) was 10.2 months; median PFS (mPFS) was 5.2 months. mOS for sorafenib 400 mg/day was 6.6 vs. 800 mg/day was 12.8 months [hazard ratio (HR), 0.59; P=0.04]; mPFS was 3.5 vs. 5.9 months, respectively (HR, 0.66; P=0.07). For Child Pugh A class (CP-A) patients, mOS was 15.8 months for 400 mg/day vs. 12.8 months for 800 mg/day (HR, 1.48; P=0.35); mPFS was 9.0 vs. 5.9 months, respectively (HR, 1.23; P=0.56). For Child Pugh B class (CP-B) patients, mOS was 5.0 months for 400 mg/day vs. 11.2 months for 800 mg/day (HR, 0.33; P=0.002); mPFS was 2.1 vs. 5.6 months, respectively (HR, 0.41; P=0.006). No differences in adverse events (AEs) were observed in CP-A vs. CP-B. CONCLUSIONS: Patients with CP-A or CP-B advanced HCC should be offered sorafenib at 400 mg twice daily with optimal management of AEs in order to improve survival.
BACKGROUND:Sorafenib is the only FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). In clinical practice, dose reductions are often required, although there are limited efficacy data related to dose modifications. Given the prevalence of HCC in South Texas, we assessed the efficacy and safety of sorafenib therapy in relation to dose and Child Pugh (CP) score. METHODS: A retrospective analysis was done of advanced HCC patients, starting sorafenib at 400 mg twice daily, or at physician discretion at 400 mg daily, with the goal of titrating to twice daily. Overall survival (OS) and progression-free survival (PFS) were assessed. RESULTS: Among 107 patients, median OS (mOS) was 10.2 months; median PFS (mPFS) was 5.2 months. mOS for sorafenib 400 mg/day was 6.6 vs. 800 mg/day was 12.8 months [hazard ratio (HR), 0.59; P=0.04]; mPFS was 3.5 vs. 5.9 months, respectively (HR, 0.66; P=0.07). For Child Pugh A class (CP-A) patients, mOS was 15.8 months for 400 mg/day vs. 12.8 months for 800 mg/day (HR, 1.48; P=0.35); mPFS was 9.0 vs. 5.9 months, respectively (HR, 1.23; P=0.56). For Child Pugh B class (CP-B) patients, mOS was 5.0 months for 400 mg/day vs. 11.2 months for 800 mg/day (HR, 0.33; P=0.002); mPFS was 2.1 vs. 5.6 months, respectively (HR, 0.41; P=0.006). No differences in adverse events (AEs) were observed in CP-A vs. CP-B. CONCLUSIONS:Patients with CP-A or CP-B advanced HCC should be offered sorafenib at 400 mg twice daily with optimal management of AEs in order to improve survival.
Authors: Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet Journal: J Hepatol Date: 2012-06-19 Impact factor: 25.083
Authors: Holly L Howe; Xiaocheng Wu; Lynn A G Ries; Vilma Cokkinides; Faruque Ahmed; Ahmedin Jemal; Barry Miller; Melanie Williams; Elizabeth Ward; Phyllis A Wingo; Amelie Ramirez; Brenda K Edwards Journal: Cancer Date: 2006-10-15 Impact factor: 6.860
Authors: R Lencioni; M Kudo; S-L Ye; J-P Bronowicki; X-P Chen; L Dagher; J Furuse; J F Geschwind; L Ladrón de Guevara; L L de Guevara; C Papandreou; A J Sanyal; T Takayama; S K Yoon; K Nakajima; F Cihon; S Heldner; J A Marrero Journal: Int J Clin Pract Date: 2012-07 Impact factor: 2.503
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Howard Safran; Kevin P Charpentier; Andreas Kaubisch; Kalyan Mantripragada; Gregory Dubel; Kimberly Perez; Katherine Faricy-Anderson; Thomas Miner; Yoko Eng; Joel Victor; Angela Plette; Joseph Espat; Pamela Bakalarski; Patti Wingate; David Berz; Denise Luppe; Diane Martel; Kayla Rosati; Santiago Aparo Journal: Am J Clin Oncol Date: 2015-02 Impact factor: 2.339
Authors: Amelie G Ramirez; Nancy S Weiss; Alan E C Holden; Lucina Suarez; Sharon P Cooper; Edgar Munoz; Susan L Naylor Journal: PLoS One Date: 2012-04-18 Impact factor: 3.240
Authors: Jennifer S Carew; Ernest C Medina; Juan A Esquivel; Devalingam Mahalingam; Ronan Swords; Kevin Kelly; Hui Zhang; Peng Huang; Alain C Mita; Monica M Mita; Francis J Giles; Steffan T Nawrocki Journal: J Cell Mol Med Date: 2010-10 Impact factor: 5.310
Authors: R Lencioni; M Kudo; S-L Ye; J-P Bronowicki; X-P Chen; L Dagher; J Furuse; J F Geschwind; L Ladrón de Guevara; C Papandreou; T Takayama; S K Yoon; K Nakajima; R Lehr; S Heldner; A J Sanyal Journal: Int J Clin Pract Date: 2013-11-28 Impact factor: 2.503
Authors: Mozhdeh Sojoodi; Lan Wei; Derek J Erstad; Suguru Yamada; Tsutomu Fujii; Hadassa Hirschfield; Rosa S Kim; Gregory Y Lauwers; Michael Lanuti; Yujin Hoshida; Kenneth K Tanabe; Bryan C Fuchs Journal: Cancer Prev Res (Phila) Date: 2020-04-06
Authors: Nicole E Rich; Christian Carr; Adam C Yopp; Jorge A Marrero; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2020-12-30 Impact factor: 11.382